There are biological and clinical questions facing the field of HIV genotyping such as the need to better define the level of sensitivity required to detect drug-resistant variants, how different ...

Drug-resistance amino acids known in HIV-1 [36] are shown in bold. Amino acids that are the same as those of the reference HIV-1 HXB2 are shown as bars. † Consensus amino acid sequences were ...

But 2024 has fueled increasing optimism among leading infectious disease experts after the results of two groundbreaking ...

The 36-patient CAPELLA trial tested lenacapavir in highly treatment-experienced HIV patients who had developed resistant to their current drugs, with virus levels rising as a result. It found that ...

NAIROBI: Concerns are heightening regarding HIV treatments losing their punch in the country as the deadly virus becomes more resistant. Health experts are now worried that if the trend of ...

Gilead Sciences has claimed FDA approval for Sunlenca, a therapy from Gilead Sciences for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, at the ...

A new long-acting preventive HIV drug could reach the world’s poorest countries by the end of 2025 or early 2026, a global health official told Reuters on Tuesday. The ambition is to start ...

Lenacapavir is approved under the brand name Sunlenca in the United States for treating HIV-1 infection in heavily treatment-experienced adults with multi-drug-resistant infections. GILD also ...

Mr Brown, who was also known as "the Berlin patient", was given a bone marrow transplant from a donor who was naturally resistant to HIV in 2007. It meant he no longer needed anti-viral drugs and ...